Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01074177 · ClinicalTrials.gov registry record · NA
Understanding Mechanisms of Acquired Resistance to BIBW2992
A NA study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 24
- Enrollment target
NCT01074177: Completed NA study, sponsored by Massachusetts General Hospital.
NCT01074177 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 24 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01074177, a NA study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 24 participants
- Enrollment target
Study Summary
In this research study we are looking to see how effective BIBW 2992 is at suppressing the development of the T790M mutation in non-small cell lung cancer (NSCLC) patients. Epidermal growth factor receptors (EGFR) are proteins found on the surface of some cancer cells that promote a growth signal. Some cancer drugs for NSCLC work to block this signal from reaching its target on the cancer cells which in turn may slow or stop the cancer from growing. However, many times patients with EGFR mutations will stop responding to these cancer drugs and develop drug-resistance because they have developed a specific EGFR mutation called T790M. BIBW 2992 may prevent the T790M mutation from becoming active and therefore slow disease progression.
Interventions
- DRUG BIBW 2992
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2011-02 |
| Est. Completion | 2017-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01074177
The ClinicalTrials.gov registry entry for NCT01074177 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BIBW 2992 is the first listed.
NCT01074177 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01074177 about?
NCT01074177 is a clinical study titled "Understanding Mechanisms of Acquired Resistance to BIBW2992". In this research study we are looking to see how effective BIBW 2992 is at suppressing the development of the T790M mutation in non-small cell lung cancer (NSCLC) patients. Epidermal growth factor receptors (EGFR) are proteins found on the surface of some cancer cells that promote a growth signal. S...
What is the current status of trial NCT01074177?
This trial is currently completed. It is a NA study. The enrollment target is 24 participants. The study started on 2011-02. Estimated completion is 2017-03.
What interventions are being tested in trial NCT01074177?
The interventions under investigation include: BIBW 2992 (DRUG).
Who is sponsoring clinical trial NCT01074177?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.